REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Regulation FD Disclosure
ITEM 7.01
|
REGULATION FD DISCLOSURE.
|
conference call to discuss recent business highlights and
financial results for the first quarter ended March 31, 2017.
Call participants encountered audio difficulties, preventing the
vast majority of participants from hearing the entire call. As
such, a copy of the script from the conference call is furnished
as Exhibit 99.1 to this report.
8-K and Exhibits 99.1 attached hereto shall not be deemed filed
for purposes of Section 18 of the Securities Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in any such filing.
|
ITEM 9.01
|
FINANCIAL STATEMENTS AND EXHIBITS.
|
|
Number
|
Description
|
|
|
99.1
|
Earnings Call Script.
|
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation. REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Recent Trading Information
REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) closed its last trading session up +1.00 at 20.30 with 189,831 shares trading hands.
